Technology and healthcare M&A activity surged 40% in early 2026 compared to the same period last year, with companies racing to acquire AI capabilities through acquisition rather than internal development. The trend spans deal sizes from mid-market to mega-cap transactions worth billions.
Danaher announced a near-$10 billion acquisition of medical device maker Masimo on February 18, marking one of the largest healthcare deals in recent years. The same day, Warner Bros. reopened acquisition talks with Paramount, signaling consolidation pressures in media and entertainment as traditional players seek scale against streaming competitors.
The wave follows major 2025 completions including Broadcom's VMware acquisition and CrowdStrike's purchases of Onum and Pangea to bolster cybersecurity AI capabilities. Illumina acquired proteomics company SomaLogic in June 2025, adding AI-driven protein analysis to its genomics platform.
Deal activity reflects two converging forces: companies seeking ready-made AI capabilities amid talent shortages, and sellers capitalizing on premium valuations before potential market corrections. Healthcare deals particularly target AI diagnostic and monitoring technologies that reduce costs while improving outcomes.
Premium-to-market multiples in tech deals averaged 35% above trading prices in early 2026, up from 28% in 2025, according to deal terms. Buyers justify higher prices by pointing to accelerated revenue growth from AI features and reduced time-to-market versus building internally.
The consolidation wave faces regulatory scrutiny in both the US and EU, with antitrust authorities examining whether mega-deals reduce competition in AI development. Three major tech acquisitions announced in late 2025 remain under review, potentially slowing completion rates for larger transactions.
Mid-market deals under $1 billion are closing faster, with an average 4.2-month timeline from announcement to completion in early 2026 versus 6.1 months in 2025. Private equity firms are backing these smaller acquisitions, betting on AI integration synergies driving returns.
The M&A surge suggests companies view 2026 as a strategic window to consolidate before AI capabilities become commoditized, making acquisitions less valuable. Deal flow is expected to continue through mid-year before potentially slowing if interest rates rise or tech valuations compress.